Cassava Sciences, Inc. (SAVA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.29 |
| Open | 1.3 |
| Day High | 1.35 |
| Day Low | 1.27 |
| 52-Week High | 4.98 |
| 52-Week Low | 1.15 |
| Volume | 134,262 |
| Average Volume | 857,770 |
| Market Cap | 63.77M |
| PE | -0.59 |
| EPS | -2.22 |
| Moving Average 50 Days | 2.12 |
| Moving Average 200 Days | 2.51 |
| Change | 0.03 |
Data not available
Cassava Announces Closure of U.S. Department of Justice Investigation
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tub
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
GlobeNewswire Inc.
Jan 13, 2026 1:00 PM GMT
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety pro
Cassava Announces Agreement to Settle Securities Class Action Litigation
GlobeNewswire Inc.
Dec 23, 2025 1:00 PM GMT
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tub